Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of NBI-1065846, used as adjunctive treatment to oral antidepressant
medication(s), compared with placebo on improving symptoms of anhedonia in subjects with
major depressive disorder (MDD).